Pemphigus Vulgaris Epidemiology Insights & Trends

• Pemphigus vulgaris is a rare autoimmune blistering disease.
• The prevalence of pemphigus vulgaris is increasing slowly due to improved patient survival and chronic disease duration, resulting in a growing pool of individuals requiring long-term disease monitoring.
• Pemphigus vulgaris is the most common form of pemphigus and occurs all over the world. Its frequency is influenced by geographic location and ethnicity. Pemphigus vulgaris occurs between 0.1 and 2.7 per 100,000 people per year.
• Pemphigus vulgaris and nonendemic pemphigus foliaceous typically occur in adults between 40-60 years old. Pemphigus is pretty rare in children (except for endemic pemphigus foliaceous, which affects children and young adults in endemic areas). Neonatal pemphigus is a rare form of pemphigus that happens when an affected mother’s autoantibodies are transferred to the fetus.
• The disease has a strong impact on quality of life, as recurrent mucocutaneous lesions, pain, and functional limitations can significantly affect daily activities and psychosocial well-being.
• Rare disease designation and limited patient numbers create challenges for epidemiological tracking, as pemphigus vulgaris is often underreported in national healthcare databases and requires specialized registries for accurate burden estimation.

Pemphigus Vulgaris Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent of Pemphigus Vulgaris: ~XX
• 2036 Projected Pemphigus Vulgaris Diagnosed Prevalent Cases: ~XX
• Pemphigus Vulgaris Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Pemphigus Vulgaris Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Pemphigus vulgaris, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Pemphigus Vulgaris Understanding and Diagnosis Algorithm

Pemphigus Vulgaris Overview

Pemphigus vulgaris is a rare, chronic, life-threatening autoimmune blistering disease characterized by the production of pathogenic autoantibodies against desmoglein-3 (DSG3) and, in many cases, desmoglein-1 (DSG1). These autoantibodies disrupt cell-to-cell adhesion between keratinocytes, resulting in fragile blisters and painful erosions affecting the mucous membranes and skin. PV most commonly presents with persistent oral ulcers followed by cutaneous blistering and, if left untreated, can lead to severe infections, fluid loss, and significant morbidity. Although its exact cause remains unknown, genetic susceptibility and environmental triggers are believed to contribute to disease development.

Further details are provided in the report...

Pemphigus Vulgaris Diagnosis

The diagnosis of pemphigus vulgaris is based on a combination of clinical presentation, histopathology, immunopathology, and serological testing. Skin or mucosal biopsy typically demonstrates suprabasal acantholysis, while direct immunofluorescence (DIF) is considered the diagnostic gold standard, revealing intercellular deposition of IgG and complement (C3). Indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA) for anti-desmoglein-1 and anti-desmoglein-3 antibodies are widely used to confirm the diagnosis, assess disease activity, and monitor treatment response. Early and accurate diagnosis is critical to prevent disease progression and reduce complications.

Further details are provided in the report...

Pemphigus Vulgaris Epidemiology

The Pemphigus Vulgaris epidemiology section offers a comprehensive analysis of the historical, current, and projected patient population across the seven major markets (7MM). It examines the factors influencing past and future epidemiological trends by incorporating findings from published studies and expert insights from key opinion leaders (KOLs). Additionally, this section of the Pemphigus Vulgaris market report presents the diagnosed patient pool, highlights evolving patient trends, and outlines the assumptions used to develop the epidemiological forecasts.

Key Findings from Pemphigus Vulgaris Epidemiological Analysis and Forecast

• Pemphigus vulgaris is most commonly diagnosed between 40–60 years of age.
• As per secondary analysis, pemphigus vulgaris  generally affects males and females similarly, although some regions report female predominance.
• Pemphigus vulgaris is estimated to have  a prevalence of ~10–20 cases/million population in the US.

Scope of the Pemphigus Vulgaris Epidemiology Report

• The report covers a segment of a descriptive overview of pemphigus vulgaris, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Pemphigus Vulgaris Epidemiology Report Insights

• Pemphigus Vulgaris Patient Population Forecast

Pemphigus Vulgaris Epidemiology Report Key Strengths

• Pemphigus Vulgaris Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Pemphigus Vulgaris Patient Burden Trends (by geography)

Explore DelveInsight's Pemphigus Vulgaris Market Insight, Epidemiology and Market Forecast – 2036 to uncover emerging therapies, epidemiology trends, and future commercial opportunities.

FAQs

• What are the disease risks, burdens, and unmet needs of pemphigus vulgaris? What will be the growth opportunities across the 7MM concerning the patient population with Pemphigus vulgaris?
• What is the historical and forecasted pemphigus vulgaris patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Pemphigus Vulgaris Epidemiology Report

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.